We are advancing cancer care by developing next-generation therapies to address treatment resistance.
Our approach has three pillars:
- Identifying clinically validated targets where there is a clear unmet medical need. This allows us to minimize the biological and clinical risk associated with the development of our product candidates.
- Structure-guided drug design with predictive screening methodologies. Our discovery engine combines a unique chemistry approach to optimize “pan-ness” combined with a novel preclinical assay that we believe can accurately predict clinical outcomes for TKIs.
- Translationally-driven, biomarker-guided clinical development. We employ biomarkers early on in clinical development, which allows us to assess activity against individual mutant variants.
Resistance mutations limit the efficacy of existing targeted therapies by rendering tumor cells unresponsive to drugs. Our next-generation TKIs may successfully address the challenge of resistance.